Harbor Capital Advisors Inc. Invests $99,000 in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)

Harbor Capital Advisors Inc. bought a new position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 30,595 shares of the company’s stock, valued at approximately $99,000. Harbor Capital Advisors Inc. owned approximately 0.07% of 4D Molecular Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of the business. KLP Kapitalforvaltning AS acquired a new position in 4D Molecular Therapeutics during the 4th quarter worth $48,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in 4D Molecular Therapeutics during the 4th quarter worth $50,000. PNC Financial Services Group Inc. lifted its holdings in 4D Molecular Therapeutics by 66.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 9,124 shares of the company’s stock worth $51,000 after buying an additional 3,630 shares in the last quarter. Daiwa Securities Group Inc. lifted its holdings in 4D Molecular Therapeutics by 5,291.8% during the 4th quarter. Daiwa Securities Group Inc. now owns 9,921 shares of the company’s stock worth $55,000 after buying an additional 9,737 shares in the last quarter. Finally, Velan Capital Investment Management LP acquired a new position in 4D Molecular Therapeutics during the 4th quarter worth $56,000. 99.27% of the stock is owned by institutional investors and hedge funds.

4D Molecular Therapeutics Stock Down 2.4%

FDMT opened at $4.39 on Monday. 4D Molecular Therapeutics, Inc. has a 12 month low of $2.24 and a 12 month high of $28.93. The company has a fifty day simple moving average of $3.45 and a 200 day simple moving average of $4.49. The stock has a market cap of $203.37 million, a P/E ratio of -1.54 and a beta of 2.84.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.02). On average, equities research analysts expect that 4D Molecular Therapeutics, Inc. will post -2.84 earnings per share for the current fiscal year.

Analyst Ratings Changes

FDMT has been the topic of several research reports. Barclays reduced their price objective on 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. Chardan Capital reduced their price objective on 4D Molecular Therapeutics from $28.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, May 9th. Royal Bank of Canada reduced their price objective on 4D Molecular Therapeutics from $39.00 to $35.00 and set an “outperform” rating on the stock in a report on Monday, March 3rd. HC Wainwright reissued a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Monday, March 3rd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, June 11th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $29.56.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.